



PRESS RELEASE, June 14, 2019

Heavily oversubscribed new issue in SelectImmune Pharma

SelectImmune Pharma's listing on the Spotlight Stock Market is now in its final phase with a very positive result. The subscription applications received encompass just over MSEK 70, which means a subscription rate of approximately 240%.

SelectImmune is grateful for the trust shown in the Company and the substantial interest in our operations. The Company's goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.

Due to the high subscription rate, the Company has secured a broad ownership group with just over 1,000 new shareholders. As a result of the new issue, the Company received a capital infusion of MSEK 30 before issue expenses, which amounted to MSEK 2.5.

Indicative timetable

Notification of allotment:

Around June 17, 2019 Only the parties receiving an allotment will be notified.

Settlement date:

June 20, 2019

Expected first day of trading for Class B shares:

June 26, 2019 with the ticker name SELECT

Expected first day of trading for subscription warrants – TO 1 B:

Following registration with the Swedish Companies Registration Office, indicatively mid-July 2019

Through the new issue, SelectImmune Pharma's share capital increased by SEK 200,000, from SEK 583,333 to SEK 783,333 and the number of shares by 4,000,000, from 11,666,660 shares to 15,666,660.

For further information, refer to the prospectus, which was approved and registered by the Swedish Financial Supervisory Authority on May 23, 2019 pursuant to the offering prior to listing on the Spotlight Stock Market.

Advisor

The Swedish branch of Arctic Securities AS is financial advisor. The firm of solicitors Delphi is legal advisor.

For more information, contact

Arctic Securities, Telephone +46 8 446 860 80

Catharina Svanborg, Chairman of the Board,
SelectImmune Pharma, Telephone +46 709
42 65 49

This information is such information that SelectImmune Pharma is required to publish under the EU Market Abuse Regulation. This information was provided to the media, through the agency of the contact person set out above, for publication on June 14, 2019.

Important notice

The information contained in this press release does not constitute an offer to acquire, subscribe or otherwise trade in shares or other securities in the Company. No action has been taken, or will be taken, to allow a public offering in any jurisdictions other than Sweden.

The information contained in this press release must not be disclosed, published or distributed, directly or indirectly, in or into the US (including its territories and provinces, each state in the United States as well as the District of Columbia ("US")), Australia, Hong Kong, Canada, Japan, New Zealand, Switzerland, Singapore or South Africa, or to persons whose participation would require additional prospectuses, registration or other measures than those imposed by Swedish law. Measures conflicting with this instruction can be considered to infringe applicable securities legislation.

No actions have been taken, or will be taken, by the Company to allow a public offering in any country other than Sweden. The securities referred to in this press release have not and will not be registered in accordance with the U.S. Securities Act from 1933 (“Securities Act”), applicable at any time, and may not be offered or sold, directly or indirectly, in or into the US or to persons residing there, except pursuant to an applicable exemption from the registration requirements of the Securities Act. The Company will not register any part of the offering in the US or make a public offering in the US to acquire the securities.

This press release is not a prospectus in accordance with Directive 2003/71/EC (this Directive, together with all amendments contained therein and applicable implementing measures in the relevant home member state in accordance with this directive, is referred to as the “Prospectus Directive”). Investors should not subscribe for securities referred to in this press release other than on the basis of information provided in the prospectus published pursuant to the Offering.

In an EEA member state, other than Sweden, that has implemented the Prospectus Directive, this information is solely intended for, and only addresses, qualified investors in such a member state as referred to in the Prospectus Directive.

This press release may contain certain forward-looking statements and opinions. Forward-looking information includes all statements that do not refer to past facts and events and such statements that relate to the future. This is particularly the case for statements concerning future financial performance, plans and expectations regarding the Company’s operations and management, future growth and profitability and the general economic and regulatory environment as well as other circumstances that impact the Company. Even if the Company considers that these statements were reasonable when they were made, these are in themselves subject to risks, uncertainty and other factors that may mean that actual events differ considerably from the expectations expressed or implied in such forward-looking statements. Potential investors shall therefore not attach inappropriate confidence in the forward-looking information contained herein, and potential

investors are strongly encouraged to read the sections of the prospectus that contain a more detailed description of factors that may impact the Company's operations and the market in which the Company operates.

The forward-looking information provided in this press release is only valid on the date of this press release and may be changed without notice. Neither the Company nor any other person assumes any responsibility to update any forward-looking statements to reflect events taking place or circumstances arising with respect to the content of this press release.